Biotech
Commented by Armin Schulz on April 2nd, 2024 | 06:45 CEST
MorphoSys, Defence Therapeutics, Novo Nordisk - Biotech deals: Corporations on a shopping spree!
In 2023, the volume of business in the pharmaceutical industry, with mergers and acquisitions, reached USD 152 billion despite high interest rates. Experts predict that this momentum could continue as large pharmaceutical companies are facing a wave of patent expiries for their key products that will roll in between 2025 and 2030. Companies are therefore on the lookout for new active ingredients, often by acquiring or licensing developments from smaller biotech companies to compensate for potential revenue shortfalls. There have also been major takeovers in recent months. We take a look at takeover targets and buyers.
Read
Commented by Armin Schulz on March 28th, 2024 | 08:45 CET
TUI, dynaCERT, Evotec - The profit is in buying
In the world of the financial markets, the timeless maxim applies: "The profit is in buying". This tried and tested stock market adage, which may seem trivial at first glance, is actually the key to financial success. Indeed, the price at which an investment is purchased often determines its subsequent triumph or failure long before the sale is even considered. Despite advances in technology and the complexity of markets, the basic lesson remains - buying wisely and at a well-considered price lays the foundation for profits. We have picked out three interesting candidates.
Read
Commented by Fabian Lorenz on March 26th, 2024 | 07:00 CET
Out of BioNTech and into Defence Therapeutics and Evotec shares?
The BioNTech share is currently out of steam. Although sentiment in the sector is improving, as star investor Cathie Wood recently invested in Moderna, the German biotech leader is not making any headway. The latest figures have not convinced analysts, and the price targets have even been further reduced. In contrast, the shares of Defence Therapeutics and Evotec appear to have more upside momentum. The Canadian cancer specialist has just raised new capital to develop its exciting pipeline. The Company has recently been granted a new US patent for its approach to cancer therapy. Evotec has a "Buy" recommendation. Could this mean the share is on the verge of an upward trend?
Read
Commented by André Will-Laudien on March 20th, 2024 | 07:30 CET
Entry prices or Sell? BioNTech, Defence Therapeutics, Lufthansa and Nvidia in focus
The stock market keeps running and running - but in reality, it is just a handful of stocks that make waves every day. Investors should now be vigilant because, like the recent correction in Bitcoin, the major indices could also fall by 10%. Of course, nobody is thinking about this at the moment; the mood is too good, almost euphoric, considering Germany's precarious economic situation. We analyze technical trends and fundamental assessments to ensure everything in your portfolio goes smoothly. In our view, BioNTech, Defence Therapeutics, and Lufthansa are on the runway, but when it comes to Nvidia, you should start deploying the parachute slowly. What is next here?
Read
Commented by André Will-Laudien on March 19th, 2024 | 06:30 CET
Pay attention now - 100% performance possible with BioNTech, Bayer, Cardiol Therapeutics or HelloFresh
For investors in the biotech sector, 2024 is starting much like the previous year ended. Everyone is waiting for the big bang, which has yet to materialize. However, now that there is no longer a pandemic and cancer research is still stuck in a rut, selection has become crucial. Investing only in the future is no longer a guarantee of profit; instead, it is much more important to identify the most innovative business models and follow them. BioNTech does not currently have a blockbuster but has a good EUR 17 billion in its coffers. Bayer has seen its share price drop fivefold since 2019, and HelloFresh is also unable to keep its promises. By contrast, Cardiol Therapeutics has experienced a true rally. What lies next here?
Read
Commented by Armin Schulz on March 13th, 2024 | 07:30 CET
HelloFresh, Royal Helium, Evotec - Rebounds in sight
Despite all the various challenges in today's world, such as geopolitical tensions or inflation, the stock market indices have managed to climb upwards. Investors are faced with a crucial question: Where is the hidden value in a market that has already broken many records? The answer could lie in those stocks that have so far stood on the sidelines of the great rally - the silent but potentially strong performers waiting for their rebound. This strategy shifts the focus away from the usual suspects who have already posted substantial gains to stocks that are ready to initiate their own rebound, potentially unlocking significant value for patient investors in the process. We have identified three such candidates.
Read
Commented by Fabian Lorenz on March 13th, 2024 | 06:30 CET
Bayer disappoints, BioNTech share gives hope, and Cardiol Therapeutics with upside potential!
Analysts were anticipating a more favourable outcome from Bayer's Capital Markets Day. While the spin-off of Aspirin and Co. was expected, and there was also more transparency in the legal disputes, the actual results differed significantly. In some cases, analysts' share price targets plummeted by nearly 50%. In contrast, analysts have renewed their "Buy" recommendation for Cardiol Therapeutics shares. The specialist in cardiovascular diseases is facing exciting weeks and the share could certainly still more than double. There is also movement at BioNTech. In addition to operating figures, there will soon be an update on the drug pipeline. The question remains whether the share can halt its downward trend.
Read
Commented by Stefan Feulner on March 11th, 2024 | 06:30 CET
Novo Nordisk, Defence Therapeutics, Bayer - Rally after the breakout?
Biotechnology has been revived after a disappointing stock market year in 2023. In addition to the interest rate cut fantasy, which should benefit the capital-intensive and innovative sector in particular, the current wave of acquisitions should lead to further price rises. Although the broad Nasdaq Biotech Index has only risen by 3% since the beginning of the year, it is currently facing key resistance levels. If these are broken through, the momentum northwards could accelerate.
Read
Commented by Armin Schulz on March 6th, 2024 | 07:00 CET
Cardiol Therapeutics is on the upswing - When will BioNTech and Evotec follow suit?
In the world of biotechnology, the stock market often resembles a rollercoaster ride where investors and companies need to be firmly strapped in. The volatility of biotech companies can include dizzying highs and lows driven by the research and development of new medical treatments and therapies. A single positive report of clinical trial results or regulatory approval of a breakthrough drug can send a company's share price soaring, sending investors and companies into euphoria overnight. This happened recently with Cardiol Therapeutics. When can Evotec and BioNTech announce a success?
Read
Commented by Juliane Zielonka on March 1st, 2024 | 17:05 CET
Cardiol Therapeutics, Bayer, Coinbase - Which share will generate profits in the long term?
The world of pharmaceuticals and life sciences is characterized by precisely documented studies in clinical research. If an active ingredient makes it to approval, there is the potential for a blockbuster worth billions. Cardiol Therapeutics has an active ingredient in the second phase of clinical research for the treatment of heart disease in people under 35 years of age. This active ingredient can also restore the quality of life of 26 million people worldwide who suffer from heart failure. Bayer continues to clean up the unresolved issues left behind by the former CEO. Did the weedkiller RoundUp® from the Monsanto deal possibly lead to improper treatment due to a lack of consumer protection information? The five-figure lawsuits still pending against Roundup are dampening the share's profit prospects. The situation is currently quite different in the cryptocurrency market. Bitcoin is outperforming everyone, and the Coinbase share is benefiting from it. Which investment generates profits in the long term?
Read